Volume 5.20 | Jun 6

Prostate Cell News 5.20 June 6, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Prostate Cancer Drug Delivers Benefits before Chemotherapy
A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival. [Press release from Oregon Health & Science University discussing online prepublication in The New England Journal of Medicine] Press Release | Abstract | Full Article
FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Attenuates Prostate Cancer Growth
In in vitro experiments, Exendin-4 significantly decreased proliferation of the prostate cancer cell lines, LNCaP, PC3 and DU145, but not that of ALVA-41. This anti-proliferative effect depended on glucagon-like peptide-1 receptor expression. [Diabetes] Abstract

Effects of Tumor-Suppressor Lysyl Oxidase Propeptide on Prostate Cancer Xenograft Growth and Its Direct Interactions with DNA Repair Pathways
In vitro studies showed that recombinant lysyl oxidase propeptide (rLOX-PP) inhibits radiation-induced activating phosphorylations of ataxia-telangiectasia mutated and checkpoint kinase 2 and that exogenously added rLOX-PP protein can localize to the nucleus in both DU145 and PC3 cells. [Oncogene] Abstract

EGFR Mediates Docetaxel Resistance in Human Castration-Resistant Prostate Cancer through the Akt-Dependent Expression of ABCB1 (MDR1)
Investigators explored the mechanism of epidermal growth factor receptor (EGFR)-mediated docetaxel resistance in prostate cancer. [Arch Toxicol] Abstract

DTX3L and ARTD9 Inhibit IRF1 Expression and Mediate in Cooperation with ARTD8 Survival and Proliferation of Metastatic Prostate Cancer Cells
Researchers identified Deltex-3-like E3 ubiquitin ligase (DTX3L), diphtheria-toxin-like ADP-ribosyltransferase-9 (ARTD9) and ARTD8 as novel oncogenic survival factors in metastatic prostate cancer (mPCa) cells. Their studies revealed that DTX3L forms a complex with ARTD8 and mediates together with ARTD8 and ARTD9 proliferation, chemo-resistance and survival of mPCa cells. [Mol Cancer] Abstract | Full Article

Identification of Beta-2 as a Key Cell Adhesion Molecule in PCa Cell Neurotropic Behavior: A Novel Ex Vivo and Biophysical Approach
Researchers determined the effect of beta-2 expression on prostate cancer (PCa) cell neurotropic metastasis associated behavior. They overexpressed beta-2 as a fusion protein with enhanced cyan fluorescence protein in weakly aggressive LNCaP cells and observed neurotropic effects utilizing our novel ex vivo organotypic spinal cord co-culture model, and performed functional assays with neural matrices and atomic force microscopy. [PLoS One] Full Article

Down-Regulation of mir-221 and mir-222 Restrain Prostate Cancer Cell Proliferation and Migration that Is Partly Mediated by Activation of SIRT1
The proliferation, apoptosis, cell cycle distinction, and migration capacity of prostate cells were determined following transfection of miR-221 or miR-222 inhibitor. The biological impact and regulation of silent information regulator 1 (SIRT1) on prostate cancer cells were investigated. [PLoS One] Full Article

Identification of Genes Regulating Migration and Invasion Using a New Model of Metastatic Prostate Cancer
Scientists used DU145 human prostate cancer cells and performed repeated rounds of orthotopic prostate injection and selection of subsequent lymph node metastases. Tumor growth, metastasis, cell migration and invasion were analyzed. [BMC Cancer] Full Article

HOXB13 Regulates the Prostate-Derived Ets Factor: Implications for prostate Cancer Cell Invasion
HOXB13 promoted PC3 cell migration and invasion. The DNA microarray analysis demonstrated that HOXB13 significantly suppressed the expression of the prostate-derived Ets factor. Accordingly, the expression of MMP-9 and survivin was regulated by HOXB13. [Int J Oncol] Abstract

Efficient Delivery of Micro RNA to Bone-Metastatic Prostate Tumors by Using Aptamer-Conjugated Atelocollagen In Vitro and In Vivo
The anticancer effect of nanoparticles in vivo was investigated using the survival times of human prostate cancer bone metastasis mice model. Luciferase assays of pGL-3 expression against PC3 and LNCaP cells showed that the transfection efficiency of the synthesized DNA/atelocollagen (ATE)-RNA aptamer complex was higher than that of the DNA/ATE complex. [Drug Deliv] Abstract

CLINICAL RESEARCH

Molecular Characterization of Enzalutamide-Treated Bone Metastatic Castration-Resistant Prostate Cancer
Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer. Researchers evaluated enzalutamide’s effects on cancer and on androgens in blood and bone marrow, and associated these with clinical observations. [Eur Urol] Abstract

Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer
Scientists utilized immunofluorescence to examine Desmoglein 2 (DSG2) expression in normal prostate and in a clinically well-characterized cohort of prostate cancer patients. Correlation of DSG2 expression with clinico-pathological characteristics and biochemical recurrence was analyzed to assess its clinical significance. [PLoS One] Full Article

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
 
REVIEWS
Beyond Androgen Deprivation Ancillary Integrative Strategies for Targeting the Androgen Receptor Addiction of Prostate Cancer
The authors propose that regimens featuring an N-terminal domain-targeting drug, various nutraceuticals/drugs that downregulate NF-κB activity, and/or supplemental intakes of fish oil, berberine, sulforaphane, and epigallocatechin-3-gallate have potential for blocking proliferation of prostate cancer by targeting its characteristic addiction to androgen receptor activity. [Integr Cancer Ther] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
SCIENCE NEWS
Tokai Pharmaceuticals Presents New Clinical Data for Galeterone among Patients with Advanced Prostate Cancer
Tokai Pharmaceuticals, Inc. announced positive interim results from the Phase II ARMOR2 study of galeterone among patients with castration-resistant prostate cancer. [Press release from Tokai Pharmaceuticals, Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago] Press Release

IMAAGEN Data Demonstrate that Abiraterone Acetate plus Prednisone (5mg Once Daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)
Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone in patients with M0-CRPC at high risk of developing metastatic disease. [Press release from Janssen Biotech, Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
 
INDUSTRY NEWS
Novogen Identifies Highly Active Drug Candidates against Prostate Cancer
Novogen Limited announced that it has achieved a key milestone with its super-benzopyran (SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. [Novogen Limited] Press Release

Conrad T. Prebys Gives $25 Million to Salk Institute to Support Scientific Research
The Salk Institute for Biological Studies has received a $25 million gift from San Diego philanthropist and former Salk trustee Conrad T. Prebys to support cutting-edge biological research on a wide range of diseases. [The Salk Institute for Biological Studies] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2014 Best of American Society of Clinical Oncology (ASCO) Boston Meeting
August 8-9, 2014
Boston, United States

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW PhD Studentship – Prostate Cancer Research (Cardiff University)

Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

Research Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

Research Coordinator / Research Assistant – Oncology (NYU Langone Medical Center Department of Pathology)

PhD Research Project – Role of Leukemia Inhibitory Factor in Prostate Cancer Bone Metastases (Nuffield Department of Surgical Sciences, University of Oxford)

Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Therapeutic Targets for Cancer Treatment (Sanford Burnham Medical Research Institute)

PhD Position – 3D Cell Culture & Microfluidics: New Insights in Prostate Cancer (CEA French Atomic and Alternative Energies Commission)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us